Clinical trials
Metastatic Prostate Cancer clinical trials
Below are recruiting metastatic prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 705 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06205316RecruitingPhase 3
Radiation therapy for returning or limited-spread prostate cancer
This trial compares two types of radiation therapy for prostate cancer that has come back or spread to a few places after surgery. The goal is to see which radiation schedule works better with fewer side effects.
Scottsdale, ArizonaAges 18 years+ - NCT06215508Recruiting
Smartwatch and geriatric assessment for older men with prostate cancer
This trial tests whether using a smartwatch along with a geriatric assessment can help doctors better manage the health of older men with metastatic prostate cancer who are about to start a new type of hormone therapy. It aims to improve quality of life and treatment outcomes.
Chicago, IllinoisAges 18 minutes+ - NCT06216249RecruitingPhase 2
Flexible dosing of Lu-PSMA for advanced prostate cancer
This trial tests a flexible dosing schedule of a targeted radiation drug (Lu-PSMA) for men with metastatic prostate cancer that has stopped responding to hormone therapy and chemotherapy. It aims to see if adjusting the treatment schedule can improve outcomes while reducing side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT06242119Recruiting
Testing a new PET scanner prototype
This study is testing a new type of PET scanner (called J-PET) to see if it works as well as current PET/CT machines. If you are already scheduled for a whole-body PET/CT scan, participating would mean your scan is done with this experimental scanner instead.
KrakowAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06244004RecruitingPhase 2
PET-guided radiation for metastatic hormone-sensitive prostate cancer
This trial tests whether using a special PET scan (FDG-PET) to find and treat only the spots where cancer has spread with targeted radiation can help men with prostate cancer that has spread but still responds to hormone therapy. It compares standard treatment alone to standard treatment plus this targeted radiation.
Chicago, IllinoisAges 18 years+ - NCT06249750RecruitingPhase 2
Heat shock therapy for castration-resistant prostate cancer
This trial tests a near-infrared whole-body heat shock technique to treat prostate cancer that no longer responds to hormone therapy. It aims to see if this heat-based approach can help control the cancer.
Hangzhou, ZhejiangAges 18–90 - NCT06260410Recruiting
Lu-PSMA prostate cancer data study
This study collects information (like scans and blood tests) from men with prostate cancer who are about to start Lu-PSMA therapy. The goal is to track how the cancer responds and learn more about its features during treatment.
Rotterdam, South HollandAges 18 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Duarte, CaliforniaAges 18–130 - NCT06288113RecruitingPhase 2
Re-treatment with 177Lu-PSMA-617 for prostate cancer
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
Los Angeles, CaliforniaAges Any age - NCT06306612Recruiting
Surgery plus hormone therapy for advanced prostate cancer
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06325046Recruiting
Adaptive radiation therapy for localized prostate cancer
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Albert Lea, MinnesotaAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT07052578Recruiting
Aggressive prostate cancer study with HRR blood test
This study looks at men with aggressive, high-volume metastatic prostate cancer that is still sensitive to hormone therapy. It will analyze a blood test for HRR gene mutations (like BRCA) to help understand treatment patterns.
ArkhangelskAges 18 years+ - NCT06330805RecruitingPhase 2
Comparing heart effects of two hormone therapies for prostate cancer
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
Columbus, OhioAges 18 years+ - NCT06347705RecruitingPhase 2
Vaccine plus standard therapy for prostate cancer before surgery
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
Basking Ridge, New JerseyAges 18 years+ - NCT06391034RecruitingPhase 2
MRI scan with pyruvate for prostate cancer
This trial uses a special MRI scan (with hyperpolarized pyruvate, a naturally occurring substance) to look at prostate cancer in more detail. It aims to help doctors understand how the cancer is responding to treatment or how it might behave.
San Francisco, CaliforniaAges 18 years+ - NCT06392295RecruitingPhase 2
PSMA-Guided Radiation for Limited Prostate Cancer Return
This trial tests whether targeted radiation to the lymph nodes in the belly can help men whose prostate cancer has returned in just a few spots after prior radiation. You must have had a PSMA PET/CT scan showing the cancer is limited to pelvic or belly lymph nodes.
Miami, FloridaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06397703RecruitingPhase 2
Testosterone Blockers and Radiation for Prostate Cancer
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
New York, New YorkAges 18 years+ - NCT06402357RecruitingPhase 2
Focused Ultrasound for Recurrent Prostate Cancer After Radiation
This trial tests if a focused ultrasound treatment can safely and effectively treat prostate cancer that has come back after radiation therapy. The ultrasound uses sound waves to heat and destroy cancer cells in a specific area of the prostate while sparing healthy tissue.
Gainesville, FloridaAges 18 years+ - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06439225RecruitingPhase 3
Chemo for prostate cancer with DNA repair changes
This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.
Calgary, AlbertaAges 18 years+
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic prostate cancer?
- Yes. Clin2 currently lists 705 recruiting metastatic prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Prostate Cancer Metastatic Disease
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.